BASTIDE LE CONFORT MÉDICAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.62 EUR | +5.13% |
|
+15.62% | -34.25% |
| Apr. 09 | BASTIDE LE CONFORT MEDICAL : EPS upgrade (2023: 0.0%, 2024: +1.6%) |  |
| Apr. 09 | Bastide: new contract with the British NHS | CF |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 281.9 | 254 | 347 | 258 | 208.9 | 130.5 | - | - |
| Enterprise Value (EV) 1 | 473.8 | 524.9 | 670.9 | 655.1 | 523.4 | 467.4 | 461.7 | 451.3 |
| P/E ratio | 62.1 x | 22 x | 26 x | 19 x | 18.8 x | 7.72 x | 5.65 x | 4.94 x |
| Yield | - | 0.78% | 0.57% | - | - | 2.67% | 2.74% | 3.03% |
| Capitalization / Revenue | 0.84 x | 0.66 x | 0.78 x | 0.55 x | 0.41 x | 0.25 x | 0.23 x | 0.22 x |
| EV / Revenue | 1.41 x | 1.37 x | 1.51 x | 1.4 x | 1.03 x | 0.88 x | 0.82 x | 0.75 x |
| EV / EBITDA | 7.54 x | 6.45 x | 7.6 x | 6.9 x | 5.15 x | 4.38 x | 4.04 x | 3.69 x |
| EV / FCF | 17.8 x | 69.6 x | 24.1 x | 183 x | 10.1 x | 18 x | 17 x | 13.9 x |
| FCF Yield | 5.62% | 1.44% | 4.15% | 0.55% | 9.94% | 5.56% | 5.88% | 7.2% |
| Price to Book | 4.44 x | 3.37 x | 4.29 x | 3.04 x | 2.43 x | 1.28 x | 1.08 x | 0.92 x |
| Nbr of stocks (in thousands) | 7,321 | 7,321 | 7,306 | 7,309 | 7,303 | 7,408 | - | - |
| Reference price 2 | 38.50 | 34.70 | 47.50 | 35.30 | 28.60 | 17.62 | 17.62 | 17.62 |
| Announcement Date | 10/14/19 | 10/29/20 | 10/18/21 | 10/18/22 | 10/18/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 335.7 | 382.7 | 444.1 | 468.3 | 508 | 530.3 | 564.3 | 600.6 |
| EBITDA 1 | 62.86 | 81.39 | 88.3 | 95 | 101.6 | 106.6 | 114.3 | 122.2 |
| EBIT 1 | 28.42 | 32.76 | 36.98 | 38.9 | 42.79 | 44.47 | 49.33 | 53.33 |
| Operating Margin | 8.46% | 8.56% | 8.33% | 8.31% | 8.42% | 8.39% | 8.74% | 8.88% |
| Earnings before Tax (EBT) 1 | 11.58 | - | - | 21.02 | 22.77 | 18.4 | 29.9 | 36 |
| Net income 1 | 5.091 | 11.6 | 13.45 | 13.68 | 12.05 | 16.83 | 22.93 | 26.23 |
| Net margin | 1.52% | 3.03% | 3.03% | 2.92% | 2.37% | 3.17% | 4.06% | 4.37% |
| EPS 2 | 0.6200 | 1.580 | 1.830 | 1.860 | 1.520 | 2.283 | 3.120 | 3.570 |
| Free Cash Flow 1 | 26.65 | 7.538 | 27.85 | 3.586 | 52.05 | 25.97 | 27.17 | 32.5 |
| FCF margin | 7.94% | 1.97% | 6.27% | 0.77% | 10.24% | 4.9% | 4.81% | 5.41% |
| FCF Conversion (EBITDA) | 42.39% | 9.26% | 31.54% | 3.77% | 51.23% | 24.36% | 23.77% | 26.59% |
| FCF Conversion (Net income) | 523.41% | 64.98% | 207.03% | 26.21% | 432.02% | 154.26% | 118.46% | 123.89% |
| Dividend per Share 2 | - | 0.2700 | 0.2700 | - | - | 0.4700 | 0.4833 | 0.5333 |
| Announcement Date | 10/14/19 | 10/29/20 | 10/18/21 | 10/18/22 | 10/18/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2023 S1 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 206.1 | 221.7 | 114.9 | - | 127.9 | 258.3 | 127.9 | 137.1 | 265 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | 17.06 | 18.77 | - | 21.45 | - | 21.34 | - | - | - |
| Operating Margin | - | 8.28% | 8.47% | - | - | - | 8.26% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | 6.117 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | 0.8400 | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/20 | 10/29/20 | 3/25/21 | 2/8/22 | - | 10/18/23 | 10/18/23 | 11/16/23 | 3/20/24 | 3/20/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 192 | 271 | 324 | 397 | 315 | 337 | 331 | 321 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.053 x | 3.328 x | 3.668 x | 4.18 x | 3.096 x | 3.16 x | 2.898 x | 2.624 x |
| Free Cash Flow 1 | 26.6 | 7.54 | 27.9 | 3.59 | 52 | 26 | 27.2 | 32.5 |
| ROE (net income / shareholders' equity) | 7.82% | 16.7% | 17.1% | 16.5% | 14% | 17.7% | 19.6% | 19.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 8.660 | 10.30 | 11.10 | 11.60 | 11.80 | 13.80 | 16.30 | 19.10 |
| Cash Flow per Share 2 | 6.980 | 10.40 | 11.40 | 12.50 | 11.50 | 11.00 | 12.20 | 13.20 |
| Capex 1 | 34.4 | 39.8 | 46.5 | 53.3 | 53.6 | 53.5 | 56.2 | 58.5 |
| Capex / Sales | 10.24% | 10.4% | 10.47% | 11.38% | 10.56% | 10.09% | 9.96% | 9.74% |
| Announcement Date | 10/14/19 | 10/29/20 | 10/18/21 | 10/18/22 | 10/18/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
17.62
EUR
Average target price
30.17
EUR
Spread / Average Target
+71.21%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.25% | 139M | |
| -3.44% | 3B | |
| 0.00% | 1.81B | |
| +1.82% | 1.53B | |
| +49.28% | 624M | |
| -3.09% | 503M | |
| -35.42% | 368M | |
| -13.04% | 136M | |
| +1.92% | 67.7M |
- Stock Market
- Equities
- BLC Stock
- Financials Bastide Le Confort Médical
